Trials / Completed
CompletedNCT01827839
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ). The data collected will be compared with the data from subjects without HZ in other HZ/su trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster vaccine (GSK1437173A) | 2 doses administered intramuscularly in deltoid region of non-dominant arm. |
Timeline
- Start date
- 2013-06-10
- Primary completion
- 2014-02-10
- Completion
- 2014-11-25
- First posted
- 2013-04-10
- Last updated
- 2018-10-18
- Results posted
- 2017-03-07
Locations
4 sites across 2 countries: Canada, Russia
Source: ClinicalTrials.gov record NCT01827839. Inclusion in this directory is not an endorsement.